
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review</strong></summary>
            <div>
                <ul><li>Purpose: Describe key principles for evaluating + managing patients w/ disorders of gut-brain interaction (DGBI) + hypermobile Ehlers-Danlos syndrome (hEDS) / hypermobility spectrum disorders (HSDs) w/ coexisting postural orthostatic tachycardia syndrome (POTS) +/or mast cell activation syndrome (MCAS).</li><li>Methods: Expert review commissioned + approved by American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee.</li><li>Guidance based on published literature + expert opinion; no systematic reviews performed.</li><li>No formal ratings for evidence quality/strength.</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of Ehlers-Danlos Syndrome (EDS) patients have the hypermobile subtype (hEDS)?</li><li>2. What is the heart rate increase threshold for diagnosing POTS in adults during an upright posture test?</li><li>3. What is the required increase in serum tryptase level from baseline to suggest mast cell activation?</li><li>4. What is the Beighton score primarily used for in gastroenterology practice regarding hEDS/HSDs?</li><li>5. In a cross-sectional survey of hEDS/HSD individuals, what percentage met diagnostic criteria for disorders of gut-brain interaction (DGBI)?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction to hEDS/HSDs, POTS, MCAS</strong></summary>
            <div>
                <ul><li>hEDS: Inherited connective tissue disorder → musculoskeletal symptoms, joint hypermobility, tissue fragility.</li><li>Most common EDS subtype: 80%-90% of EDS patients.</li><li>Part of larger HSDs group: common pain + joint hypermobility, but not meeting hEDS criteria.</li></ul>
                
        <details>
            <summary><strong>GI Symptoms in hEDS/HSDs</strong></summary>
            <div>
                <ul><li>GI symptoms frequently reported in hEDS/HSDs.</li><li>Associated w/ ↓ quality of life + ↑ healthcare utilization.</li><li>98% of hEDS/HSD patients in one survey met DGBI criteria.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Overlapping Syndromes</strong></summary>
            <div>
                <ul><li>Growing literature links hEDS/HSDs w/ POTS + MCAS.</li><li>Data limited to observational studies, often lacking rigorous diagnostic criteria.</li><li>Clinicians face challenges in recognizing + treating GI symptoms in these comorbid conditions.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Pathophysiology &amp; Associations</strong></summary>
            <div>
                <ul><li>Theoretical mechanistic link exists between hEDS/HSDs, POTS, MCAS.</li><li>Experimental evidence for biological mechanisms is limited + evolving.</li><li>Clinicians should be aware of observed associations + overlapping GI manifestations (BPA 1).</li></ul>
                
        <details>
            <summary><strong>hEDS/HSDs Mechanisms</strong></summary>
            <div>
                <ul><li>Skin biopsies in hEDS/HSDs + classical EDS → altered collagen fibril structure.</li><li>Collagen changes → fibroblast dysfunction w/ altered adhesion + cytoskeletal response.</li><li>Connective tissue in hEDS is softer + less stiff than controls.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS Mechanisms</strong></summary>
            <div>
                <ul><li>Mast cells derived from multipotential hematopoietic stem cells.</li><li>Differentiate into progenitors → migrate into connective tissue + mucosa.</li><li>Proliferate into mast cells containing granules (histamine, heparin, cytokines, proinflammatory molecules).</li></ul>
                
        <details>
            <summary><strong>Mast Cell Degranulation</strong></summary>
            <div>
                <ul><li>Early/excessive degranulation → mast cell activation disorders.</li><li>Causes multisystemic symptoms: skin, soft tissue, GI tract, respiratory tract, cardiovascular system.</li><li>MCAS: subtype of mast cell activation disorder.</li></ul>
                
        <details>
            <summary><strong>MCAS Definition</strong></summary>
            <div>
                <ul><li>Characterized by mast cell activation ← triggers (food, heat, emotion, mechanical stimuli).</li><li>Due to abnormal sensitivity of mast cells w/o mast cell proliferation.</li><li>Symptoms typically involve ≥ 2 body systems (e.g., GI tract, skin, cardiac, nervous system).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>POTS Mechanisms</strong></summary>
            <div>
                <ul><li>Form of dysautonomia → impaired autonomic responses.</li><li>Leads to clinical symptoms of orthostatic intolerance.</li><li>Autonomic nervous system innervates every organ → controls HR, BP, body temperature.</li></ul>
                
        <details>
            <summary><strong>Dysfunction Sites</strong></summary>
            <div>
                <ul><li>Dysfunction @ various levels: peripheral nerves, autonomic ganglia, spinal cord, brain.</li><li>Results in cardiac, respiratory, alimentary, urinary, reproductive, ocular, sudomotor defects.</li><li>Different POTS phenotypes: hypovolemic, neuropathic, primary hyperadrenergic.</li></ul>
                
        <details>
            <summary><strong>POTS in hEDS/HSDs</strong></summary>
            <div>
                <ul><li>Patients w/ hEDS/HSDs commonly experience autonomic dysregulation + orthostatic intolerance.</li><li>Mechanistic basis not fully understood; may be confounded by medications (e.g., stimulants).</li><li>Theorized roles: vascular laxity +/or peripheral neuropathy.</li><li>Newer evidence implicates possible autoimmune etiologies.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Observed Associations &amp; Prevalence</strong></summary>
            <div>
                <ul><li>hEDS/HSDs patients may have ↑ incidence of MCAS + POTS vs. general population.</li><li>Study of 139 MCAS patients w/ refractory GI symptoms: 23.7% had EDS, 25.2% had POTS, 15.1% had both.</li><li>Small study: 1/3 of POTS patients reported IBS diagnosis.</li><li>Survey of 616 hEDS/HSDs patients: 37.5% reported POTS diagnosis.</li></ul>
                
        <details>
            <summary><strong>GI Symptoms w/ Comorbid POTS</strong></summary>
            <div>
                <ul><li>Study investigating hEDS/HSDs: &gt;60% had ≥ 1 GI symptom.</li><li>Those w/ concomitant POTS more likely to have fibromyalgia, IBS, GERD, or dysmotility.</li><li>Caveat: hEDS/HSDs diagnosis often not based on 2017 criteria in these studies.</li><li>MCAS + POTS not always categorically established; further investigation needed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Mechanisms of DGBI Symptoms</strong></summary>
            <div>
                <ul><li>Many common DGBI mechanisms likely contribute to GI symptoms in hEDS/HSDs, POTS, MCAS.</li><li>Mechanisms: altered motility, visceral hypersensitivity, immune activation, altered secretion, disordered central processing.</li><li>Some evidence suggests unique predisposition to altered sensorimotor functions + central processing.</li></ul>
                
        <details>
            <summary><strong>Autoimmune Dysfunction</strong></summary>
            <div>
                <ul><li>Possible role for autoimmune dysfunction in common pathogenesis of these conditions.</li><li>Pasricha et al. demonstrated this recently.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>hEDS/HSDs &amp; GI Physiology</strong></summary>
            <div>
                <ul><li>Changes in collagen structure/extracellular matrix molecules → changes in intestinal motility, tone, sensation, permeability.</li><li>Retrospective studies: high prevalence of abnormal GI transit + structural/functional pelvic floor abnormalities in EDS.</li><li>Inconsistent reports: some studies show no differences in gastric emptying/accommodation or anorectal physiology.</li><li>Prospective studies on GI physiology in hEDS/HSDs are lacking.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>POTS &amp; GI Physiology</strong></summary>
            <div>
                <ul><li>Dysautonomia (incl. POTS) pathophysiology may involve GI motor dysfunction + visceral sensitization.</li><li>One study (163 patients): 2/3 of POTS patients w/ GI symptoms had abnormal gastric emptying.</li><li>Retrospective study: ↑ prevalence of delayed small bowel transit + hypocontractility patterns in POTS (wireless motility capsule).</li><li>Others described impaired gastric myoelectrical activity + central sensitization in POTS.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS &amp; GI Physiology</strong></summary>
            <div>
                <ul><li>Low-grade inflammation, barrier dysfunction, visceral hypersensitivity may be relevant in MCAS patients w/ DGBI symptoms.</li><li>Aguilera-Lizarraga et al. demonstrated mast cell activation → local IgE antibodies against dietary antigens → visceral sensitization.</li><li>Mast cells may modulate nociception in common DGBIs (e.g., IBS, functional dyspepsia).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Features &amp; Risk Factors</strong></summary>
            <div>
                <ul><li>When to suspect hEDS/HSDs, POTS, +/or MCAS in DGBI patients.</li></ul>
                
        <details>
            <summary><strong>hEDS/HSDs Diagnostic Criteria (2017)</strong></summary>
            <div>
                <ul><li>International consensus guideline defines hEDS/HSDs by 3 major criteria (BPA 3).</li></ul>
                
        <details>
            <summary><strong>Criterion 1: Generalized Hypermobility</strong></summary>
            <div>
                <ul><li>Assessed using the Beighton score (screening tool).</li><li>Gastroenterologists should consider incorporating Beighton score into practice.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Criterion 2: Connective Tissue Manifestations</strong></summary>
            <div>
                <ul><li>Presence of ≥ 2 of the following:</li><li>- Other connective tissue disorder manifestations (e.g., soft/velvety skin, striae, pelvic organ/rectal prolapse in children/men/nulliparous women).</li><li>- Family history.</li><li>- Musculoskeletal complications (e.g., joint instability, widespread pain).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Criterion 3: Exclusion of Other Conditions</strong></summary>
            <div>
                <ul><li>Absence of unusual skin fragility (prompts exclusion of other EDS forms).</li><li>Exclusion of other heritable/acquired connective tissue disorders.</li><li>Exclusion of other joint disorders involving hypotonia +/or connective tissue laxity.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>POTS Diagnostic Criteria &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Defined in adults as ↑ HR ≥ 30 beats/min within 10 min of upright posture (- orthostatic hypotension).</li><li>In adolescents (12-19 yrs): ↑ HR ≥ 40 beats/min.</li><li>Symptoms of orthostatic intolerance must be present for ≥ 6 months.</li><li>Symptoms should not be explained by dehydration, medications, diet, primary anxiety, eating disorders, or other medical conditions.</li></ul>
                
        <details>
            <summary><strong>Common POTS Symptoms</strong></summary>
            <div>
                <ul><li>Palpitations, tremulousness, lightheadedness, fatigue, blurred vision, generalized weakness.</li><li>Cognitive + bladder dysfunction, GI symptoms are not uncommon.</li><li>GI symptoms (nausea, abdominal pain, vomiting, diarrhea, bloating, severe constipation) common.</li><li>Nausea, pain, early satiety are most predictive of abnormal GI motility.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS Classification &amp; Symptoms</strong></summary>
            <div>
                <ul><li>Part of a debated global classification: primary, secondary, idiopathic types (Table 1).</li><li>Generation of vasoactive + inflammatory mediators (histamine, cytokines, chemokines) → allergic reactions + various symptoms.</li><li>GI symptoms of MCAS often overlap w/ DGBIs (e.g., nausea, vomiting, heartburn, dysphagia, abdominal pain, atypical chest pain, bowel dysfunction).</li></ul>
                
        <details>
            <summary><strong>MCAS Classification (Table 1 Summary)</strong></summary>
            <div>
                <ul><li>Primary Clonal MCAS: Most mast cells display CD25 + KIT D816V8a mutation detected.</li><li>- W/ confirmed cutaneous mastocytosis (CM) or systemic mastocytosis (SM).</li><li>- W/ only 2 minor SM criteria (SM/CM not fulfilled).</li><li>Secondary MCAS: IgE mediated, or related to other hypersensitivity/immunologic disorder.</li><li>- Absence of neoplastic mast cells or KIT D816V8 mutation.</li><li>Idiopathic MCAS: Criteria for MCAS met, but absence of clonal mast cells or IgE-mediated allergy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Consensus Guideline for MCAS (Table 1 Summary)</strong></summary>
            <div>
                <ul><li>A) Typical clinical signs of severe, recurrent (episodic) systemic MC activation (≥ 2 organ systems, often anaphylaxis).</li><li>B) Involvement of MCs documented by biochemical studies: ↑ serum tryptase level from baseline to +20% + 2 ng/mL (preferred marker).</li><li>C) Response of symptoms to therapy w/ MC-stabilizing agents, drugs against MC mediator production, or drugs blocking mediator release/effects.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Other MCAS Symptoms</strong></summary>
            <div>
                <ul><li>Fatigue, tinnitus, conjunctivitis, headaches (incl. migraines), brain fog, palpitations, flushing, pruritus, urticaria, myalgias, lymphadenopathy.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Prior Infection as Risk Factor for Dysautonomia</strong></summary>
            <div>
                <ul><li>Up to 40% of POTS patients self-report viral upper respiratory or GI infection as precipitating event.</li><li>Association between acute + long COVID-19 + POTS described.</li><li>Immunologic cause for POTS supported by ↑ prevalence of autoimmune disease in POTS patients + family members.</li><li>↑ frequency of nonspecific autoantibodies (e.g., cardiovascular G protein–coupled membrane receptors, ganglionic acetylcholine receptors, antinuclear antibody, Sjogren’s antibodies) + antibodies to norepinephrine, acetylcholine, angiotensin II.</li></ul>
                
        <details>
            <summary><strong>COVID-19 &amp; GI Dysmotility</strong></summary>
            <div>
                <ul><li>Evidence: COVID-19 virus exhibits neuronal tropism + may induce GI dysmotility via COVID-induced angiotensin converting enzyme 2 depletion.</li><li>Differences in gut microbiome between controls, POTS, + post-COVID syndrome patients.</li><li>Microbiota composition associations w/ IBS symptoms.</li><li>History of infectious insult may prompt consideration for POTS/MCAS, as gastroparesis, functional dyspepsia, IBS also → prior infection.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Evaluation</strong></summary>
            <div>
                <ul><li>Evaluation of GI symptoms/DGBI in hEDS/HSDs patients w/ POTS +/or MCAS should largely follow general population recommendations (BPA 8).</li><li>Strategy: positive symptom-based approach, limited noninvasive testing.</li><li>Careful attention to individual factors (diet, lifestyle, psychological distress) + drugs (opioids) underlying chronic GI symptoms.</li></ul>
                
        <details>
            <summary><strong>Screening for Joint Hypermobility</strong></summary>
            <div>
                <ul><li>Gastroenterologists should inquire about joint hypermobility.</li><li>Strongly consider incorporating Beighton score as a screening tool (BPA 3).</li><li>If screen positive: consider applying 2017 diagnostic criteria for hEDS or refer to specialist.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Celiac Disease Testing</strong></summary>
            <div>
                <ul><li>Risk of celiac disease ↑ in hEDS/HSDs +/or POTS vs. general population.</li><li>Serological testing for celiac disease + endoscopic biopsies may be considered earlier in hEDS/HSDs patients w/ various GI symptoms (not just diarrhea) (BPA 9).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopy Safety</strong></summary>
            <div>
                <ul><li>Rates of endoscopy-related complications (e.g., perforation) do not appear ↑ among adults w/ hEDS/HSDs (except vascular EDS).</li><li>Age- + indication-appropriate endoscopic evaluation should be performed.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Opioid Use</strong></summary>
            <div>
                <ul><li>For chronic pain, opioid medications should be avoided.</li><li>If already prescribed: manage through careful multidisciplinary approach.</li><li>Facilitate opioid cessation where possible.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Food-Related Symptoms &amp; Diet Testing</strong></summary>
            <div>
                <ul><li>Food-related symptoms (incl. exacerbation of dysautonomia + orthostatic intolerance) described in EDS + HSDs.</li><li>Theorized symptoms → physiologic responses (e.g., splanchnic vasodilation).</li><li>Insufficient research on prevalence of specific food-mediated mechanisms (e.g., disaccharidase deficiencies) in hEDS/HSDs.</li><li>Routine testing for carbohydrate maldigestion/malabsorption not supported (BPA 9).</li></ul>
                
        <details>
            <summary><strong>Mast Cell-Mediated Pain</strong></summary>
            <div>
                <ul><li>Aguilera-Lizarraga et al. described mast cell-dependent mechanisms of abdominal pain → dietary antigens.</li><li>Conceivable mast cell dysfunction may underlie GI symptoms (incl. visceral hypersensitivity) in hEDS/HSDs.</li><li>Validated clinical tests for mast cell–mediated abdominal pain are lacking.</li><li>Limited evidence for MCAS-specific tests (serum tryptase, mast cell staining on biopsies) for isolated GI symptoms w/o generalized mast cell disorder.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>GI Motility Testing</strong></summary>
            <div>
                <ul><li>DGBI may exist along continuum w/ other altered GI sensorimotor functions, relevant in hEDS/HSDs, POTS, MCAS.</li><li>Retrospective studies: GI dysmotility relatively common in hEDS/HSDs.</li><li>Enrichment of EDS gene variants described in idiopathic gastroparesis.</li><li>Reports inconsistent; others failed to show clear ↑ risk of abnormal GI sensorimotor function in hEDS/HSDs.</li><li>Currently, GI motility testing guided by symptoms + responses to first-line treatments.</li><li>No clear evidence for alternative approach to motility testing in hEDS/HSDs.</li></ul>
                
        <details>
            <summary><strong>Earlier Motility Testing Considerations</strong></summary>
            <div>
                <ul><li>Reasonable to consider earlier testing of gastric motor functions (gastric emptying/accommodation) in patients w/ coexisting POTS (BPA 11).</li><li>Underlying autonomic dysfunction may predispose to gastroparesis or GI motility perturbations.</li><li>Diagnostic testing for functional defecation disorders (anorectal manometry, balloon expulsion test, defecography) should be considered in hEDS/HSDs w/ lower GI symptoms (e.g., incomplete evacuation) (BPA 10).</li><li>High prevalence of pelvic floor dysfunction, esp. rectal hyposensitivity, in this population.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>POTS Evaluation</strong></summary>
            <div>
                <ul><li>Evaluation for POTS may be performed w/ appropriate clinical history (BPA 2).</li><li>When POTS suspected: assess for exaggerated orthostatic tachycardia using postural vital signs (BPA 4).</li><li>Consider referral for autonomic function testing (tilt table, sudomotor testing) + expanded lab testing w/ autoantibodies if POTS confirmed.</li><li>Postural vital signs: symptomatic ↑ HR ≥ 30 beats/min w/ 10 min standing during active stand or head-up tilt table test (- orthostasis).</li></ul>
                
        <details>
            <summary><strong>POTS Testing Indications</strong></summary>
            <div>
                <ul><li>Considered in hEDS/HSDs patients w/ refractory GI symptoms + orthostatic intolerance.</li><li>After exclusion of medication side effects + attempted lifestyle/behavioral modifications (e.g., adequate hydration, physical exercise).</li><li>Not required for all hEDS/HSDs patients reporting GI symptoms alone.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS Evaluation</strong></summary>
            <div>
                <ul><li>Testing for mast cell disorders (incl. MCAS) should be considered in hEDS/HSDs + DGBI patients (BPA 5).</li><li>Patients must present w/ episodic symptoms suggesting generalized mast cell disorder.</li><li>Symptoms: visceral/somatic pain, pruritus, flushing, sweating, urticaria, angioedema, wheezing, tachycardia, abdominal cramping, vomiting, nausea, diarrhea, urogynecological + neurological complaints.</li><li>Involving ≥ 2 physiological systems (e.g., cutaneous, GI, cardiac, respiratory, neuropsychiatric).</li></ul>
                
        <details>
            <summary><strong>MCAS Testing Limitations</strong></summary>
            <div>
                <ul><li>Current data do not support routine use of these tests for GI symptoms in all hEDS/HSDs patients.</li><li>No clinical/laboratory evidence of primary/secondary mast cell disorder.</li><li>If MCAS suspected: diagnostic testing w/ serum tryptase levels collected @ baseline + 1-4 hours following symptom flares (BPA 6).</li><li>↑ of 20% above baseline + 2 ng/mL necessary to demonstrate mast cell activation.</li></ul>
                
        <details>
            <summary><strong>Referral for Confirmed MCAS</strong></summary>
            <div>
                <ul><li>If MCAS diagnosis supported by clinical +/or laboratory features: refer to allergy specialist or mast cell disease research center (BPA 7).</li><li>Additional testing may be performed: urinary N-methylhistamine, leukotriene E4, 11b-prostaglandin F2.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Mast Cell Staining on Biopsies</strong></summary>
            <div>
                <ul><li>Some proposed counting mast cells per high power field from intestinal biopsies.</li><li>Threshold distinguishing normal from abnormal mast cell counts is debated.</li><li>CD-117 immunohistochemical staining thought to be more sensitive marker in duodenum (second portion) or ileum.</li><li>Consensus for these guidelines, even among allergists, is controversial.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management Strategies</strong></summary>
            <div>
                <ul><li>Few clinical trials guide management of GI symptoms in hEDS/HSDs, POTS, or MCAS.</li><li>Management largely follows general DGBI treatment principles.</li><li>Addition of specific treatments for orthostatic symptoms in POTS + mast cell activation symptoms.</li><li>Management should be supportive + symptom-focused.</li><li>Follow principles of integrated/multidisciplinary care, focusing on multisystemic nature of conditions (BPA 12).</li></ul>
                
        <details>
            <summary><strong>General Principles</strong></summary>
            <div>
                <ul><li>Avoidance/cessation of opioids in pain-predominant features.</li><li>Psychological support w/ brain-gut behavioral therapies.</li><li>↑ rates of anxiety + vulnerabilities to psychological distress in hypermobility, possibly mediated by autonomic dysfunction.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>GI Symptom Management (Table 2 Summary)</strong></summary>
            <div>
                <ul><li>Focus on treating most prominent GI symptoms + abnormal GI function test results.</li><li>Similar to DGBI + GI motility disorder management.</li></ul>
                
        <details>
            <summary><strong>Nausea/Vomiting</strong></summary>
            <div>
                <ul><li>Antiemetics: ondansetron, promethazine, prochlorperazine, aprepitant, off-label carbidopa.</li><li>Prokinetics: metoclopramide, domperidone, erythromycin, prucalopride, pyridostigmine (off-label prucalopride).</li><li>Complementary medicine: aromatherapies, ginger tea, STW5.</li><li>Caution: monitor for QT prolongation w/ multiple therapeutic agents.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Abdominal Pain</strong></summary>
            <div>
                <ul><li>Acid suppression: PPIs, H2RAs.</li><li>Antispasmodics: hyoscyamine, dicyclomine, peppermint oil.</li><li>Neuromodulators: TCAs, SSRIs, SNRIs, neuroleptics, anticonvulsants.</li><li>Psychological therapies: CBT, hypnotherapy, relaxation therapies.</li><li>Caution: opiates should not be used specifically to treat abdominal pain.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Constipation</strong></summary>
            <div>
                <ul><li>Fiber supplements: psyllium, methyl cellulose.</li><li>Osmotic laxatives: PEG 3350, lactulose, milk of magnesia.</li><li>Stimulant laxatives: bisacodyl, senna.</li><li>Chloride channel activator: lubiprostone.</li><li>Guanylate cyclase-C agonists: linaclotide, plecanatide.</li><li>5-HT4 agonist: prucalopride.</li><li>Sodium hydrogen exchanger 3 inhibitor: tenapanor.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diarrhea</strong></summary>
            <div>
                <ul><li>Dietary modification: low FODMAP, gluten-free, soluble fiber.</li><li>Microbiome modification: rifaximin, Bifidobacterium infantis 35624.</li><li>Antidiarrheals: loperamide, diphenoxylate.</li><li>Bile acid sequestrants: cholestyramine, colestipol, colesevelam.</li><li>Mixed opioid receptor agonist/antagonist: eluxadoline (contraindicated w/ ≥ 3 alcoholic beverages/day, post-cholecystectomy, moderate-to-severe hepatic insufficiency).</li><li>5-HT3 receptor antagonist: alosetron (female patients only).</li><li>Cholinesterase inhibitors: pyridostigmine.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Pelvic Floor Symptoms</strong></summary>
            <div>
                <ul><li>Common in hEDS/HSDs.</li><li>Treat according to general principles for anorectal disorders.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>POTS Treatment</strong></summary>
            <div>
                <ul><li>Treatment of orthostatic symptoms (may include GI symptoms) (BPA 13).</li><li>Lifestyle: ↑ fluid (2 L/d) + salt intake (10 g/d), exercise training, compression garments.</li><li>Pharmacological treatment for severe cases: fludrocortisone, midodrine, beta-blockers.</li><li>Integrated care w/ multiple specialties (e.g., cardiology, neurology) for non-responders to conservative measures.</li></ul>
                
        <details>
            <summary><strong>POTS Pharmacological Treatments (Table 2 Summary)</strong></summary>
            <div>
                <ul><li>Blood volume expanders: fludrocortisone, desmopressin, erythropoietin.</li><li>Heart rate lowering agents: propranolol, ivabradine.</li><li>Central nervous system sympatholytics: clonidine, methyldopa.</li><li>Other: midodrine, pyridostigmine, droxidopa, modafinil.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS Treatment</strong></summary>
            <div>
                <ul><li>When MCAS suspected (allergic reactions + characteristic symptoms) (BPA 14).</li><li>First-line: nonsedating H1 histamine + H2 histamine receptor antagonists.</li><li>Second-line: oral cromolyn mast cell stabilizers +/or leukotriene receptor antagonists.</li><li>Avoid triggers: certain foods, alcohol, strong smells, temperature changes, mechanical stimuli (e.g., friction), emotional distress (e.g., pollen, mold), specific medications (e.g., opioids, NSAIDs, iodinated contrast).</li><li>Response rates to antimediator treatment estimated @ 75% for diarrhea, 82% for abdominal pain (unreliable estimates, expert opinion-based).</li><li>Role of immunotherapy remains under active study.</li></ul>
                
        <details>
            <summary><strong>MCAS Pharmacological Treatments (Table 2 Summary)</strong></summary>
            <div>
                <ul><li>H2 receptor antagonist: famotidine, nizatidine, ranitidine.</li><li>Second-generation H1 antagonist: cetirizine, levocetirizine, fexofenadine, loratadine.</li><li>Mast cell stabilizer: cromolyn sodium, ketotifen (not FDA approved, can be compounded).</li><li>Leukotriene receptor antagonist: montelukast.</li><li>Corticosteroids or immunoglobulins for autoimmunity (refer to allergy/immunology or mast cell specialists).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Nutritional Support &amp; Diet</strong></summary>
            <div>
                <ul><li>Special attention to nutrition + hydration; dietitian involvement frequently needed.</li><li>Screen for weight loss + disordered eating.</li><li>Special diets for symptom improvement frequently used, but efficacy studies lacking (BPA 15).</li></ul>
                
        <details>
            <summary><strong>Specific Diets</strong></summary>
            <div>
                <ul><li>Gastroparesis/small particle diet: advised if upper GI symptoms (nausea, vomiting) predominate.</li><li>Modified food composition, consistency, volume.</li><li>Lower GI symptoms: dietary advice for IBS + other bowel disorders (e.g., low fermentable carbohydrates, wheat-/gluten-free, low-histamine diets).</li><li>Efficacy in hEDS/HSDs, POTS, MCAS requires further study.</li><li>Dietary interventions w/ appropriate nutritional counseling/guidance to avoid restrictive eating pitfalls.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Severe Symptoms &amp; Malnutrition</strong></summary>
            <div>
                <ul><li>For severe symptoms, weight loss, or dehydration despite optimal medical management:</li><li>Parenteral fluid +/or enteral/parenteral nutrition sometimes necessary as stabilizing measure.</li><li>Administer through multidisciplinary model.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>MCAS Trigger Avoidance</strong></summary>
            <div>
                <ul><li>Reduce exposure to triggers: physical sensitivities (temperature, UV radiation), antigenic sensitivities (pollen, mold), food/alcoholintolerances.</li><li>Low-histamine, gluten-free, dairy-free diets recommended based on clinical experience (formal studies absent).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Management w/o POTS/MCAS</strong></summary>
            <div>
                <ul><li>Management of chronic GI symptoms in hEDS/HSDs patients w/o POTS or MCAS symptoms should align w/ existing DGBI + GI motility disorder approaches in general population (BPA 16).</li><li>Includes integrated multidisciplinary care involving multiple specialties (e.g., cardiology, rheumatology, dietician, psychology).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Summary &amp; Future Directions</strong></summary>
            <div>
                <ul><li>Accumulating evidence suggests DGBI/GI motility disorders, hEDS/HSDs, POTS, MCAS may be linked.</li><li>Mechanisms explaining associations not fully understood.</li><li>Gastroenterology providers should be aware of hEDS/HSDs, POTS, MCAS features.</li><li>Recognize full complexity of patients w/ multisystemic symptoms.</li><li>Offer informed counseling + guide patients away from unreliable sources/fragmented care.</li><li>Foster therapeutic relationships + evidence-based care.</li></ul>
                
        <details>
            <summary><strong>Key Considerations for Providers</strong></summary>
            <div>
                <ul><li>Early diagnostic testing of gastric motor or anorectal functions may be considered.</li><li>Treatment of POTS symptoms.</li><li>Use of histamine receptor antagonists.</li><li>Referral to allergy specialist or mast cell research center may be considered in some cases.</li><li>Overall approach should follow general recommendations for DGBI + GI motility disorder management.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Future Research Needs</strong></summary>
            <div>
                <ul><li>Identify biological mechanisms connecting these disorders.</li><li>Develop new diagnostic tools.</li><li>Identify novel therapeutics (e.g., immunotherapy).</li><li>Optimize care + improve long-term outcomes.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
